×
Apparently, Edgar Wright Turned Down Directing an ‘X-Men’ Movie

Apparently, Edgar Wright Turned Down Directing an ‘X-Men’ Movie

Director Edgar Wright has a short, but storied, history with Marvel Studios. The Shaun of the Dead director, whose new film The Running Man just opened, was famously going to make Ant-Man way back in Phase One. Then, of course, there were creative differences, and that movie happened without him, but fans always try to imagine, “What if?” Well, apparently, there’s an even bigger Marvel “What if?” for Edgar Wright than Ant-Man. There’s the X-Men.

Speaking on the red carpet for The Running Man, producer Simon Kinberg revealed that his desire to work with Wright over the years led to many different projects being floated his way, including everyone’s favorite mutants. “I’ve been trying to make a movie with Edgar Wright for over 25 years,” Kinberg said to the official Movies X account. “We met when we were young guys in Hollywood, just starting out together, and I’ve been such a huge fan of his. I’ve sent him things over the years, many, many [things], X-Men movies, all kinds of things, and he always said no.” Until The Running Man. Here’s the full quote.

Kinberg, who is currently writing a Star Wars trilogy, either wrote or produced every X-Men movie from 2006 to 2020. Basically, the bulk of the Fox years. And he was able to get some stellar directors to help those, from Matthew Vaughn and James Mangold to Tim Miller and David Leitch. But can you imagine Edgar Wright doing X-Men: First Class? Or Deadpool? Or New Mutants? Well, maybe not that last one.

We don’t know which films, specifically, Kinberg offered, but he definitely made it seem like more than one. And we don’t know why Wright turned them down, though his past with Marvel could’ve factored in. But, in a comic book landscape of almosts, an Edgar Wright X-Men movie is pretty damn fascinating.

Of course, Kinberg did eventually get to work with Wright on The Running Man, which you can see in theaters. Read our interview with Wright about it here, where he talks about hearing from Kinberg.

Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.



Source link
#Apparently #Edgar #Wright #Turned #Directing #XMen #Movie

Samsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech">Samsung’s new foldable display is harder to crease and damageSamsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech

Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech">Samsung’s new foldable display is harder to crease and damage

Samsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI">OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at B | TechCrunch
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about 0 million at a  billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.







Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised 0 million at a .8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a .1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI">OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B | TechCrunch

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI

Post Comment